Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Celularity Incorporated
With
This Phase 1/2 study evaluated the safety and potential efficacy of CYNK-001, an allogeneic natural killer (NK) cell therapy derived from human placental CD34+ cells, in adult patients with moderate COVID-19. Participants received intravenous infusions of CYNK-001 on Days 1, 4, and 7. CYNK-001 IV infusions administered at an initial desensitizing dose of 150 × 106 cells on Day 1 followed by a dose of 600 × 106 cells on Days 4 and 7 plus best supportive care. The study was designed to include a Phase 1 dose-escalation portion followed by a randomized Phase 2 portion; however, due to early termination, only Phase 1 participants were enrolled and treated.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted